Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
McKesson
UBS
US Army
Cantor Fitzgerald
Citi
Teva
Boehringer Ingelheim
Mallinckrodt
Queensland Health

Generated: January 23, 2018

DrugPatentWatch Database Preview

BRIVIACT Drug Profile

« Back to Dashboard

Which patents cover Briviact, and what generic alternatives are available?

Briviact is a drug marketed by Ucb Inc and is included in three NDAs. There are three patents protecting this drug.

This drug has one hundred and forty-four patent family members in forty-one countries.

The generic ingredient in BRIVIACT is brivaracetam. One supplier is listed for this compound. Additional details are available on the brivaracetam profile page.
Summary for BRIVIACT
International Patents:144
US Patents:3
Applicants:1
NDAs:3
Suppliers / Packagers: 1
Bulk Api Vendors: 19
Clinical Trials: 3
Patent Applications: 246
Drug Prices:see details
DailyMed Link:BRIVIACT at DailyMed
Drug patent expirations by year for BRIVIACT
Pharmacology for BRIVIACT
Mechanism of ActionEpoxide Hydrolase Inhibitors

US Patents and Regulatory Information for BRIVIACT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-005 May 12, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-005 May 12, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-002 May 12, 2016 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-003 May 12, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-003 May 12, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Ucb Inc BRIVIACT brivaracetam SOLUTION;INTRAVENOUS 205837-001 May 12, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-002 May 12, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Ucb Inc BRIVIACT brivaracetam SOLUTION;INTRAVENOUS 205837-001 May 12, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-004 May 12, 2016 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ucb Inc BRIVIACT brivaracetam SOLUTION;ORAL 205838-001 May 12, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for BRIVIACT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,713,635 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Subscribe
7,692,028 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses ➤ Subscribe
7,217,826 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Subscribe
7,358,276 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses ➤ Subscribe
6,806,287 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Subscribe
6,858,740 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Subscribe
6,969,770 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Subscribe
8,034,958 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for BRIVIACT

Supplementary Protection Certificates for BRIVIACT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C1001 France ➤ Subscribe PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: EU/1/15/1073 20160118
0815 Netherlands ➤ Subscribe PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: EU/1/15/1073 20160118
2016013,C1265862 Lithuania ➤ Subscribe PRODUCT NAME: BRIVARACETAMAS; REGISTRATION NO/DATE: EU/1/15/1073 20160114
/2016 Austria ➤ Subscribe PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: EU/1/15/1073 (MITTEILUNG) 20160118
90009-4 Sweden ➤ Subscribe PRODUCT NAME: BRIVARACETAM; REG. NO/DATE: EU/1/15/1073 20150114
2016013 Lithuania ➤ Subscribe PRODUCT NAME: BRIVARACETAMAS; REGISTRATION NO/DATE: EU/1/15/1073 20160114
2016 00013 Denmark ➤ Subscribe PRODUCT NAME: BRIVARACETAM; REG. NO/DATE: EU/1/15/1073/001-022 20160118
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Citi
McKesson
Cantor Fitzgerald
Merck
Cerilliant
Express Scripts
Daiichi Sankyo
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot